The FDA has approved ColoSense, a noninvasive colorectal cancer screening test, for adults 45 years of age and older who are at average risk of developing colorectal cancer.

Isatuximab plus carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) produced durable responses in transplant-eligible patients with newly diagnosed multiple myeloma in a phase 2 trial.

HRR testing is underused in patients with metastatic castration-resistant prostate cancer, a large study suggests.

Some experts say the recommended doses for drugs like sotorasib are too high, and they are advocating for a change in how cancer drugs are dosed. They want to do away with the concept of the maximum ...

Second-line treatment with venetoclax costs less than second-line BTK inhibitor treatment for chronic lymphocytic leukemia, data suggest.

Patients with concomitant congestive heart failure or sleep apnea were more likely to experience voiding dysfunction after NMIBC treatment.

Lymph node-positive (pN1) prostate cancer is a heterogeneous disease with varying mortality risks, investigators reported at the American Urological Association 2024 annual meeting (AUA 2024) in San ...

The FDA is reviewing the biologics license application for a new subcutaneous formulation of Opdivo (nivolumab).

Nearly two-thirds of patients with advanced urothelial cancer treated at oncology clinics across the US did not proceed to second-line therapy after first-line treatment.

The FDA is expected to make decisions about therapies for small-cell lung cancer and myelodysplastic syndrome next month. The US Food and Drug Administration (FDA) is expected to decide in June ...

A new study suggests that starting a patient on preferred targeted therapy within 1 year of metastatic non-small cell lung cancer diagnosis can still improve overall survival, when compared to other ...

Change Healthcare expects full operations to resume next year, according to its chief financial officer. Two months after a ...